Navigation Links
Grant to fund research into eradicating the leukemia stem cell
Date:7/14/2010

The leukemia stem cellthe root cause of all acute leukemias represents a small population of cells in patients that are difficult to eliminate with standard treatments available today. Though current chemotherapy can produce temporary remission in leukemia survivors, they remain at risk of experiencing a recurrence and dying from the disease. The one exception is the remarkable cure of a rare form of leukemia called acute promyelocytic leukemia (APL), which came about from combining differentiation therapy with chemotherapy, and was pioneered by the collaboration between scientists at the Samuel Waxman Cancer Research Foundation (SWCRF) and the Shanghai Institute of Hematology (SIH) in China in 1982.

Now, a three-year grant of $375,000 from the Emerald Foundation, Inc. will further expand the collaboration between researchers from the SWCRF and researchers at the SIH. The SWCRF/Emerald Foundation, Inc. Global Collaborative Grant will fund critical research to identify new and more powerful drugs that can restore normal differentiation and cell growth to leukemia stem cells.

"The Emerald Foundation, Inc. seized the opportunity to partner with the Samuel Waxman Cancer Research Foundation in order to develop a cure for cancer. We truly believe in SWCRF's collaborative Institute Without Walls, which is made up of internationally-recognized scientists," said Gloria Thakuria, the scientific program officer at the Emerald Foundation, Inc. "It is through the collaboration between foundations, as well as the collaborations between scientists around the world that we will discover a cure for this deadly disease."

Gwen Darien, the executive director of the Foundation, agreed. "Collaboration is a hallmark of the Waxman Foundation's 35-year history, and has helped lead the SWCRF to make significant breakthroughs in cancer research," said Darien. "We are truly excited about partnering with the Emerald Foundation, Inc. in this collaborative grant to improve the lives of patients and families worldwide."

The grant will fund the following research projects:

  • The development and testing of a compound extracted from medicinal herbs known as Oridonin and its derivatives to attack the leukemia stem cell in clinical trials.

  • The utilization of mass sequencing analyses to better understand the leukemia stem cell.

  • Identification of leukemia stem cells in acute myeloid leukemia for further research in disease progression and treatment response.

The Foundation's mission has long focused on supporting cancer research that offers patients minimally toxic treatments, said Samuel Waxman, M.D., the scientific director of the SWCRF. "Eradicating the leukemia stem cell is the next logical step to fulfilling the Foundation's mission and goal of improving the quality of life and care for cancer patients," he said.


'/>"/>

Contact: Jenny Song
jsong@waxmancancer.org
212-867-4502
Samuel Waxman Cancer Research Foundation
Source:Eurekalert

Related biology news :

1. LSUHSC awarded $2 million dollar grant to prevent pneumonia linked to immune deficiency
2. The Samuel Waxman Cancer Research Foundation awards $1.54 million in research grants for 2010-2011
3. MSU researchers awarded $9.1 million grant to battle malaria in Malawi
4. Dr. Jayne Fulkerson receives $3.2 million NIH grant
5. NSF grant will develop new online hub for biochemistry, molecular biology educators
6. CIMIT announces $3 million in medical research grants
7. NHLBI grants $1.47 million to study red blood cell transfusion storage times and bioactivity
8. University of Chicago Press book wins Grantham Prize
9. NYU Langone Medical Center receives $5.4 million NYSTEM grant for stem cell research
10. Team of UC scientists awarded $2 million NIH grant for better flu diagnoses
11. Major magnet grant to advance state-of-the-art in chemical analysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/28/2016)... Synaptics (NASDAQ: SYNA ), a leading developer of human interface ... 31, 2015. --> --> ... percent compared to the comparable quarter last year to $470.5 million. ... million, or $0.93 per diluted share. --> ... of fiscal 2016 grew 9 percent over the prior year period ...
(Date:1/22/2016)... 2016 http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ... the  "Global Behavioral Biometric Market 2016-2020" ... http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced the ... Market 2016-2020"  report to their offering. ... http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced the addition ...
(Date:1/20/2016)... , Jan. 20, 2016   MedNet Solutions ... the entire spectrum of clinical research, is pleased to ... MedNet,s significant achievements are the result of the company,s ... iMedNet eClinical , it,s comprehensive, easy-to-use and ... --> Key MedNet growth achievements in ...
Breaking Biology News(10 mins):
(Date:2/5/2016)... , Feb. 5, 2016 Australian-US drug discovery and ... today the appointment of a new Chairman, Mr John ... , effective immediately. James Garner , has ... Director and former Acting CEO, Mr Iain Ross , ... Director. --> James Garner , has also been ...
(Date:2/4/2016)... , ... February 04, 2016 ... ... presented by Bloomsburg University’s Digital Forensics Club, takes place February 5-6 at ... event features 20+ speakers and activities such as workshops and competitions for ...
(Date:2/4/2016)... , Feb. 4, 2016 ContraVir Pharmaceuticals, Inc. ... the development and commercialization of targeted antiviral therapies, announced ... Investor Conference 2016, to be held February 8-9, 2016, ... Group,s 2016 Disruptive Growth & Healthcare Conference, taking place ... 10-11, 2016. James Sapirstein , Chief Executive ...
(Date:2/4/2016)... (PRWEB) , ... February 04, 2016 , ... Many of ... for over 10 years. What sets them apart from other cuvette manufacturers is ... posted on their website. On top of this steady flow of inside information, ...
Breaking Biology Technology: